Welcome to Intradigm Corporation
Intradigm is a private biotechnology company committed to the development of systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company’s expertise in drug development and delivery serves as the foundation of Intradigm’s RNAi platform. In particular, the company’s novel and proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.
At present, Intradigm is working to build a high-value internal pipeline of RNAi oncology therapeutics. Analysts currently estimate 2007 global oncology sales of greater than $50 billion.
The company is also establishing collaborative relationships with pharmaceutical and biotechnology companies through which Intradigm’s targeted RNAi delivery technology can be applied to a broad range of therapeutic targets.
|
